Online inquiry

IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ105MR)

This product GTTS-WQ105MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ105MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2374MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ770MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ779MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ2896MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ7886MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ14339MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ14629MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ197MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 12-IgG1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW